anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to the technical field of gene engineering and aims to provide a eukaryon expression vector combining technologies of LIFRalpha-CT3 (Leukemia Inhibitory Factor Receptor alpha)-(Cell Therapy 3) and TAT-PTD (Transactivator of Transcription-Protein Transduction Domain) and application thereof to preparing a medicament for inhibiting leukemia cell proliferation. The eukaryon expression vector provided by the invention comprises nucleotide sequences shown as SEQ ID NO: 1. The invention also provides a CHO (Chinese Hamster Ovary) cell line transfected by the eukaryon expression vector. The invention also relates to a polypeptide 190CT3 produced by utilizing the CHO cell line. The polypeptide 190CT3 has very high stability and transmembrane property, and can remarkably improve the problems of poor targeting property, easy resistance to medicaments and difficulty of endocytosis/endoeukaryon of medicaments, which are caused by all-trans retinoic acid and routine chemotherapy, in the clinical promyelocytic leukemia treatment. Vitro tests prove that the 190CT3 can penetrate through a cell membrane and a nuclear membrane quickly when the 190CT3 directly acts on acute promyelocytic leukemia cells, and further inhibit the proliferation of the cells and promote the cells to differentiate into mature granular cells.
This group received R-CHOP regimen as the first-line chemotherapy. Rituximab, 375mg/m2, iv, d0; Cyclophophamide, 750mg/m2, iv, d1; Doxorubicin, 50mg/m2, iv, d1; Vincristine, 2mg/m2 (max 2mg), iv, d1; Prednisone, 100mg, po, d1-5. Repeat every 21 days for 6-8 cycles or until the criteria of terminating treatment was met.
The application discloses a yfdH gene mutant and application thereof in preparation of L-valine, and belongs to the technical field of biology. The technical problem to be solved is how to increase the yield of the L-valine of the escherichia coli. In order to solve the technical problem, the application provides a protein with an amino acid sequence shown as SEQ ID No.4, a coding gene thereof, related biological materials and application thereof in improving the yield of L-valine. The application constructs the over-expression mutant yfdH  T743C  Recombinant bacteria of the gene or the wild yfdH gene, and point mutation recombinant bacteria, and experimental results show that: overexpression of yfdH Gene or yfdH  T743C  The gene can obviously improve the yield of L-valine. Point mutation (T-C) of yfdH gene also contributes to the improvement of L-valine production. The genetic engineering strain constructed by the method can obviously promote accumulation of L-valine and improve the yield of L-valine.
The invention belongs to the field of national medicine, and discloses a Yao medicinal composition capable of tonifying kidney and producing semen and a preparation method thereof. The Yao medicinal composition comprises the following raw materials in parts by weight: 2-20 parts of fructus rosae laevigatae, 2-20 parts of cistanche, 2-20 parts of medlar, 2-20 parts of polygala fallax hemsl, 3-30 parts of morinda officinalis how, 2-20 parts of cuscuta japonica, 2-20 parts of rhizoma acori graminei and 2-20 parts of rhizoma curculiginis. The form of the Yao medicinal composition is powder, tea bags or medicinal liquor. The preparation method comprises the following steps: smashing, baking, disinfecting and sterilizing raw herbal materials, preparing into powder or tea bags or soaking with 30-degree or 60-degree edible white spirit to be prepared into the medicinal liquor. The clinical tests show that the Yao medicinal composition has the effects of improving the quality of sexual life, improving the sexual function and adjusting the balance. The Yao medicinal composition is quick and stable in curative effect, is free of toxic and side effect, and is health protection medicine capable of tonifying kidney and producing semen.
INTRODUCTION: Diabetic kidney disease (DKD) is one of the prominent microvascular complications of diabetes and the leading cause of end-stage renal disease. Inflammation plays a crucial role in the development and progression of DKD. Currently, only a few studies depict the landscape of infiltrating immune cells and their potential regulatory network in DKD. To gain a better understanding of the role of immune cells in the renal microenvironment, we sought to reveal the profile of infiltrating immune cells and their potential regulatory network in DKD.
METHODS: We obtained the transcriptomes and the corresponding clinical data of 19 DKD and 25 control samples from the Gene Expression Omnibus and Nephroseq databases, respectively. Thereafter, we conducted an analysis on the infiltrating immune cells and identified immune-related differentially expressed genes through bioinformatics. Finally, correlation analyses among immune cells, immune genes, and clinical manifestations were performed, and differentially infiltrating immune cell subsets were verified through multiplex immunofluorescence staining.
RESULTS: We demonstrated the landscape of infiltrating immune cells in patients with DKD and identified the top five hub immune regulatory genes (C3, IL7R, TYROBP, BMP2, and CXCL6). Three of the core genes (C3, BMP2, and CXCL6) were significantly correlated with the estimated glomerular filtration rate. Through multiplex immunofluorescence staining, we verified that macrophage numbers were remarkably elevated, whereas Treg cells were remarkably reduced in diabetic kidney tissues. Th2 cells were scarce in the kidney tissue.
CONCLUSION: Collectively, our findings shed light on new, possible therapeutic strategies for DKD, from an immune microenvironment perspective.
Donation and reinfusion of 1 unit whole blood and 130 mL packed red blood cells, respectively. Blood samples were collected at 8 weeks prior to donation for 12 subjects and 2 weeks prior to donation by 12 subjects. Blood samples were collected 3, 7, 14, 21, and 28 days after donation and 3, 6, 24 hours and 2, 3 and 6 days after reinfusion of blood.
BACKGROUND: Despite the growing popularity of cementless total knee arthroplasty (TKA) in younger patients, the outcomes are unclear in the elderly population. We aimed to compare the clinical outcomes and survivorship of cementless TKA between different age groups.
METHODS: Utilizing our prospectively collected institutional database, we retrospectively reviewed all patients undergoing primary cementless TKAs at a tertiary care institute. We identified 347 TKA, which were divided into 3 groups based on age at the time of surgery. Group A was ≤ 60 years, Group B was 60 to ≤ 70 years, and Group C was > 70 years. We compared clinical outcomes (Knee Society Clinical Rating System [KSCRS], Western Ontario and McMaster University Osteoarthritis Index [WOMAC], and Veterans Rand 12 Item Health Survey [VR-12]) and survivorship between the groups.
RESULTS: At final follow-up, range of motion, KSCRS, WOMAC, and VR-12 physical score were comparable (P > .05). The VR-12 Mental score was higher in Group B and Group C than in Group A (P = .003). Compared to preoperative scores, the change in KSCRS, WOMAC, and VR-12 physical and mental scores was comparable at the final follow-up (P > .05). No patient underwent revision for aseptic loosening.
CONCLUSIONS: There were no cases of revision surgery for aseptic loosening in our cohort of 347 cementless TKAs. Patients > 70 years of age undergoing cementless TKA can achieve clinical scores equivalent to those of younger patients at short term (2-year) follow-up. Longer-term survivorship is still required, but based on early data, cementless TKA can be a safe option for older patients.
In accordance with the present invention, a novel class of substituted aryl compounds (containing ether, ester, amide, ketone or thioether substitution) that promote the release of ligands involved in neurotransmission have been discovered. The present invention relates, for example, to a compound of the formula A-B-D-E-G, wherein A = 2-chloro-4-hydroxyphenyl, B = not present, D = -S-, E = -CH2CH2-, and G = pyrrolidino wherein Y is not present, n = 2, m = 0 and RD is hydrogen or methyl. In a particular aspect, compounds of the present invention are capable of modulating acetylcholine receptors. The compounds of the present invention are capable of displacing one or more acetylcholine receptor ligands, e.g., 3H-nicotine, from mammalia n neuronal membrane binding sites. Invention compounds may act as agonists, partial agonists, antagonists or allosteric modulators of acetylcholine receptors. Therapeutic indications for compounds with activity at acetylcholine receptors include diseases of the central nervous system such as Alzheimer's disease and other diseases involving memory loss and/or dementia (including AIDS dementia); cognitive dysfunction (including disorde rs of attention, focus and concentration), disorders of extrapyramidal motor function such as Parkinson's disease, progressive supramuscular palsy, Huntington's disease, Gilles de la Tourette syndrome and tardive dyskinesia; mood and emotional disorders such as depression, anxiety and psychosis; substance abuse including withdrawal symptoms and substitutio n therapy; neurocrine disorders and dysregulation of food intake, including bulimia and anorexia; disorders or nociception and control of pain; autonomic disorders including dysfunction of gastrointestinal motility and function such as inflammatory bowel disease, irritable bowel syndrome, diarrhea, constipation, gastric acid secretion and ulcers; pheochromocytoma, cardiovascular dysfunction including hypertension and cardiac arrhythmias, a s well as co-medication uses in surgical applications.
This research protocol will recruit patients with arthritis and related conditions for the purpose of screening patients for treatment protocols, and evaluating the natural history of arthritis and related conditions. Patients will be evaluated clinically, radiographically and serologically, and standardized data will be uniformly collected on all patients. Additional imaging using sensitive MRI methods will be obtained in some patients. The collected blood and tissue will be utilized for laboratory studies to continue research on the pathogenic mechanisms of rheumatoid arthritis and related autoimmune joint diseases. Data from the history and physical examination as well as several disability questionnaires in the adult and pediatric population will be used to phenotypically characterize these patients and assess outcome and functional status. Any medical care recommended or provided to the patients will be consistent with routine standards of practice and provided in consultation with the patient's referring physician.
OBJECTIVE: Whether gastric metaplasia (GM) of the oesophagus should be considered as Barrett's oesophagus (BO) is controversial. Given concern intestinal metaplasia (IM) may be missed due to sampling, the UK guidelines include GM as a type of BO. Here, we investigated whether the risk of misdiagnosis and the malignant potential of GM warrant its place in the UK surveillance.
DESIGN: We performed a thorough pathology and endoscopy review to follow clinical outcomes in a novel UK cohort of 244 patients, covering 1854 person years of follow-up. We complemented this with a comparative genomic analysis of 160 GM and IM specimens, focused on early molecular hallmarks of BO and oesophageal adenocarcinoma (OAC).
RESULTS: We found that 58 of 77 short-segment (<3 cm) GM (SS-GM) cases (75%) continued to be observed as GM-only across a median of 4.4 years of follow-up. We observed that disease progression in GM-only cases and GM+IM cases (cases with reported GM on some occasions, IM on others) was significantly lower than in the IM-only cases (Kaplan-Meier, p=0.03). Genomic analysis revealed that the mutation burden in GM is significantly lower than in IM (p<0.01). Moreover, GM does not bear the mutational hallmarks of OAC, with an absence of associated signatures and driver gene mutations. Finally, we established that GM found adjacent to OAC is evolutionarily distant from cancer.
CONCLUSION: SS-GM is a distinct entity from SS-IM and the malignant potential of GM is lower than IM. It is questionable whether SS-GM warrants inclusion in BO surveillance.
The present disclosure relates to bifunctional compounds, which find utility as modulators of alpha-synuclein (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/ inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure. Such diseases or disorders are alpha-synucleinopathies or neurodegenerative diseases associated with alpha-synuclein accumulation and aggregation, such as e.g. Parkinson Disease, Alzheimer's Disease, dementia, dementia with Lewy bodies or multiple system atrophy, in particular Parkinson's Disease.
###  Carcinogenesis

The carcinogenicity of procarbazine hydrochloride in mice, rats and monkeys has been reported in a considerable number of studies. Instances of a second nonlymphoid malignancy, including lung cancer and acute myelocytic leukemia, have been reported in patients with Hodgkin's disease treated with procarbazine in combination with other chemotherapy and/or radiation. The risks of secondary lung cancer from treatment appear to be multiplied by tobacco use. The International Agency for Research on Cancer (IARC) considers that there is "sufficient evidence" for the human carcinogenicity of procarbazine hydrochloride when it is given in intensive regimens which include other antineoplastic agents but that there is inadequate evidence of carcinogenicity in humans given procarbazine hydrochloride alone.

###  Mutagenesis

Procarbazine hydrochloride has been shown to be mutagenic in a variety of bacterial and mammalian test systems.

###  Impairment of Fertility

Azoospermia and antifertility effects associated with procarbazine hydrochloride administration in combination with other chemotherapeutic agents for treating Hodgkin's disease have been reported in human clinical studies. Since these patients received multicombination therapy, it is difficult to determine to what extent procarbazine hydrochloride alone was involved in the male germcell damage. The usual Segment I fertility/reproduction studies in laboratory animals have not been carried out with procarbazine hydrochloride. However, compounds which inhibit DNA, RNA and/or protein synthesis might be expected to have adverse effects on gametogenesis. Unscheduled DNA synthesis in the testis of rabbits and decreased fertility in male mice treated with procarbazine hydrochloride have been reported.
The first dose is 4 \~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications ≥ 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg.
The Remove-A-Tan! Process. The Remove-A-Tan! Process consists of three steps and 4 products: The Remove-A-Tan! remover is placed on the Remove-A-Tan sponge and used to instantly commence removal of the sunless tanner from the skin. The remover contains a combination of orange, lemon and lime extracts as well as sea salt. After rinsing, the Remove-A-Tan! body wash is then used for restoring moisture and soothing the skin. It contains soothing ingredients, such as Aloe Vera, Cucumber and Honey. Immediately after rinsing and drying, the Remove-A-Tan! body lotion is applied. It contains moisturising ingredients such as Vitamin E, Olive oil and Avocado extracts and honey. The process fast returns the skin to a condition where it is a able to receive the benefits of natural sunlight. It leaves the skin soft, clean smelling beautiful and feeling refreshed; leaves a non-greasy residue; avoids harsh scrubbing; and saves time and effort.
Part 2: All patients from Part 1 who have not progressed after three cycles receive standard fixed dose Durvalumab (1500 mg) on Day 1 of each 28-day treatment cycle by IV infusion in combination with orally administered low-dose Lenalidomide (10 mg) on Days 1 to 21 until documented disease progression. Study treatment is given for a maximum of 13 cycles.
This arm is optional based on Cohort 1. All participants in Cohort 2 will be receiving VIR-2218 monotherapy.
The present invention relates to a pharmaceutical composition which contains nonsteroidal anti-inflammatory active ingredients is conveniently used and maximally absorbed into the affected part, and reduces skin irritation by forming a film when applying the pharmaceutical composition to an affected part; and a method of preparing the pharmaceutical composition. The pharmaceutical composition for forming a film of the present invention comprises: a) one or more nonsteroidal anti-inflammatory active ingredients; b) a film forming material; c) a C_8-C_24 fatty acid alcohol; d) a surfactant; and e) a C_2-C_4 alcohol having a boiling point of 100°C or less. The pharmaceutical composition is conveniently used since the pharmaceutical composition is not sticky like an existing external preparation, and is not coated on cloth or the like by rapidly forming the film when being applied to the affected part. Further, the pharmaceutical composition can be easily applied even to regions such as finger joint, knee and elbow where a patch such as a plaster is difficult to be attached. Further, the pharmaceutical composition can maximize treatment efficiency by remarkably increasing drug absorption into the affected part from a formulation, and can minimize abnormal skin symptoms such as rubefaction and the like although the pharmaceutical composition is applied to the skin for a long time since the pharmaceutical composition is less skin irritant. Therefore, the present invention can provide a pharmaceutical composition which is conveniently used and effective in patients expecting an anti-inflammatory effect with respect to osteoarthritis, shoulder periarteritis, myalgia and peritenonitis symptoms.
PURPOSE:To obtain a new cysteine protease inhibitor having a high cysteine protease inhibitory effect, capable of inhibiting bone resorption by osteoclast and useful as a raw material of a food and a medicine. CONSTITUTION:A cysteine protease inhibitor having following properties; (1) Binding properties to immobilized carboxymethylated papain. (2) Inhibitory activity on papain. (3) 57+ or -5KDa molecular weight (by SOS-PAGE). (4) Positive to PAS staining. This inhibitor can be obtained by adding NaCl to milk and treating it with carboxymethylated papain fixed to a carrier.
It has been discovered that reducing, inhibiting or preventing the expression of immunosuppressive cytokines or tolergenic agents in antigen presenting cells improves the ability of the antigen presenting cell to promote an immune response. One embodiment provides a genetically engineered antigen presenting cell that has reduced or no expression of IL-10. Preferred antigen presenting cells are dendritic cells. Expression of IL-10 can be inhibited or blocked by genetically engineering the antigen presenting cell to express inhibitory nucleic acids that inhibit or prevent the expression mRNA encoding immunosuppressive cytokines. Inhibitory nucleic acids include siRNA, antisense RNA, antisense DNA, microRNA, and enzymatic nucleic acids that target mRNA encoding immunosuppressive cytokines. Immunosuppressive cytokines include, but are not limited to IL-10, TGF-β, IL-27, IL-35, or combinations thereof. Tolerogenic agents include but are not limited to indoleamine 2,3-dioxygenase.
The Philips Respironics investigational device VitaBreath is a handheld, battery powered, intermittent positive airway pressure device that is non-invasive, and provides positive airway pressure (PAP) of 18 cm water (H2O) during inspiration and 8 cm H2O on expiration, thus creating 10 cm H2O of pressure support. Pressure support is defined as the difference between inhalation pressure and exhalation pressure. The study device is intended as an adjunct therapy to relieve shortness of breath in COPD patients who experience exertion-related dyspnea to allow them to be more active. The air is delivered to the patient via a mouthpiece on the device.
Acute overdosage with oxycodone can be manifested by respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, bradycardia, hypotension, and death.

Deaths due to overdose have been reported with abuse and misuse of Oxycodone HCl Controlled-Release Tablets, by ingesting, inhaling, or injecting the crushed tablets. Review of case reports has indicated that the risk of fatal overdose is further increased when Oxycodone HCl Controlled-Release Tablets are abused concurrently with alcohol or other CNS depressants, including other opioids.

In the treatment of oxycodone overdosage, primary attention should be given to the re-establishment of a patent airway and institution of assisted or controlled ventilation. Supportive measures (including oxygen and vasopressors) should be employed in the management of circulatory shock and pulmonary edema accompanying overdose as indicated. Cardiac arrest or arrhythmias may require cardiac massage or defibrillation.

The pure opioid antagonists such as naloxone or nalmefene are specific antidotes against respiratory depression from opioid overdose. Opioid antagonists should not be administered in the absence of clinically significant respiratory or circulatory depression secondary to oxycodone overdose. In patients who are physically dependent on any opioid agonist including Oxycodone HCl Controlled-Release Tablets, an abrupt or complete reversal of opioid effects may precipitate an acute abstinence syndrome. The severity of the withdrawal syndrome produced will depend on the degree of physical dependence and the dose of the antagonist administered. Please see the prescribing information for the specific opioid antagonist for details of their proper use.